Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

March 2020 Newsletter


We realize that you take your philanthropy seriously, and we are honored by your belief in our mission and our efforts to end Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS). The accomplishments contained in the following, OMF 2019 Year in Review, are only possible because of you; your investment in our work and your dedication to our shared vision of a world free from ME / CFS. We are grateful beyond words…

OMF 2019 Year in Review
Organizational Accomplishments

We Welcomed:

  • New SAB members: Alain Moreau, PhD and Michael Snyder, PhD
  • New Chief Medical Officer: Ronald Tompkins, MD, ScD
  • New VP of Philanthropy: Kathleen Morgen
  • New Ambassadors: Karin Alvtegen and Jaqueline Ko

We also:

  • Launched a new ME / CFS Collaborative Research Center at Uppsala University in Sweden
  • Sponsored two productive scientific symposia at Stanford and Harvard
  • Sponsored two Community symposia
  • Provided free live streaming at Stanford Community symposia
  • Published high-level research papers on multiple projects
  • Established OMF Canada
  • Assembled Harvard-affiliated Clinicians to explore new collaborations among specialists



Your 2019 contribution funded open and collaborative research across the globe, conducted with impeccable standards and integrity,
by researchers and clinicians of the highest caliber.



Directed by Ronald W. Davis, PhD,
Professor of Biochemistry and of Genetics

Open Medicine Foundation has been the lead funding partner of Dr. Davis’s ME / CFS research at Stanford University since 2014.

2019 Research Focus:

  • Nanoneedle technology development
  • Technology to detect Red Blood Cell Deformability
  • Tryptophan Metabolic Trap
  • Trace heavy metal detection
  • Expanding the pathogens detected in the cell free DNA/RNA test
  • Direct DNA sequencing of genes opposable connected to ME / CFS

2019 Publications Include:

Please visit our website for more information about projects at the Stanford CRC

Read Stanford’s Year-End Message



Co-Directed by Ronald G. Tompkins, MD, ScD
Sumner M. Redstone Professor of Surgery, Harvard Medical School Founding Director





Co-Directed by Wenzhong Xiao, PhD

Assistant professor of Bioinformatics and Director of the Inflammation & Metabolism Computational Center at Massachusetts General Hospital

In 2018, OMF launched a funding partnership with Harvard affiliated hospitals, including Massachusetts General Hospital (MGH), Brigham and Women’s Hospital (BWH), and Beth Israel Deaconess Medical Center (BIDMC).

This research collaboration seeks to conduct clinical and basic science studies to characterize the dynamic biological changes that occur during a change in symptom expression of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) patients

Projects launched in 2019 include:

  • BWH iCPET biorepository plasma proteomic and metabolomic studies
  • PASS/CAT diagnostic tool development
  • Symposiums Science and Community

Please visit our website for more information about projects at the Harvard CRC



Directed by Jonas Bergquist, MD, PhD
Full Chair Professor in Analytical Chemistry and Neurochemistry

In 2019, OMF funded and launched the ME / CFS Collaborative Research Center at Uppsala University under the direction of Jonas Bergquist, MD, PhD.

This new Collaborative Center focuses on the targeted molecular diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) with the goal of evidence-based strategies for interventions.

Current projects include:

    • Kynurenine studies in ME / CFS
    • Autoimmunity aspects of ME / CFS
    • Endocrine hormone disturbances in ME / CFS

Please visit our website for more information about projects at the Uppsala CRC


We are proud to have been recognized in 2019 by Great Nonprofits,
and to have received Platinum level recognition from GuideStar
for our commitment to organizational transparency.

We look forward to 2020 with Hope for All!







Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager